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Urinary tract infections (UTIs) are among the most common bacterial infections affecting women. UTIs are primarily caused by
Escherichia coli, which increases the likelihood of a recurrent infection. We encountered two cases of recurrent UTIs (rUTIs) with
a positive E. coli culture, not improving with antibiotics due to the development of antibiotic resistance. An alternative therapeutic
regimen based on parsley and garlic, L-arginine, probiotics, and cranberry tablets has been given.This regimen showed a significant
health improvement and symptoms relief without recurrence formore than 12months. In conclusion, the case supports the concept
of using alternative medicine in treating rUTI and as a prophylaxis or in patients who had developed antibiotic resistance.
1. Introduction
The urinary tract is a sterile environment in healthy people
and remains one of the most susceptible sites for bacterial
infections [1]. About 50% of women experience a UTI
compared to 12% for men, with a recurrence rate of 25%
within 6–12 months [2, 3]. An uncomplicated UTI is one
that does not progress to a severe disease in a normal host
with no functional or anatomical abnormalities of the urinary
tract, and its primary treatment is for symptomatic relief [4].
Furthermore, the predominant etiology of uncomplicated
UTIs in young women is the uropathogenic Escherichia
coli (UPEC), representing more than 80% of the cases
and increasing the likelihood of a recurrent UTI [3, 5].
Recurrent UTIs are defined as two uncomplicated infections
occurring within six months or 3 infections within one year
after the treatment and complete resolution of the previous
symptomatic infection [6]. Evidently, antibiotics are the most
commonly prescribed treatment forUTIs, and those suffering
from recurrent UTI are given low prophylactic antibiotic
doses [7]. However, a major concern arises due to the
increased rates of resistance to treatment of UTIs, which
makes their management more challenging while seeking the
use of more expensive and less effective drugs [8, 9].
This paper reports two cases of females who were treated
with a regimen of dietary supplements after being diagnosed
with recurrent UTIs resistant to most antibiotics and showed
full healing.
2. Case 1
A 28-year-old female presents with a history of rUTI,
which started at the age of 11. She suffered symptoms of
severe constipation that she treated with herbal laxatives.
She experienced episodes of fatigue, pubic pain, loss of
appetite, malaise, dysuria, polyuria, urinary incontinence,
and macroscopic hematuria. The frequency and severity of
the symptoms increased with age, and its recurrence has
shifted from occurring once every year to once every 2-3
months after she started having regular sexual intercourse. In
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addition, she suffered from dyspareunia and urgent urination
that were aggravated after tampons usage. Pelvic ultrasound
did not show any renal calculi or bladder enlargement, yet it
revealed signs of interstitial cystitis.
Different antibiotics were given for treatment including
ciprofloxacin (500mg b.i.d), ofloxacin (200mg b.i.d) or nor-
floxacin (400mg b.i.d), cefuroxime (500mg b.i.d), or am-
oxicillin/clavulanic acid (1 g b.i.d). Resistance was developed
to these drugs and others were given aiming to prevent
the recurrence such as nitrofurantoin (100mg bid) and
fosfomycin (3 g/day), to which she was sensitive. However,
the symptoms of interstitial cystitis persisted despite the
antibiotic therapy and the patient developed candidiasis that
was resolved with fluconazole (150mg) taken every 5 days
after starting antibiotic treatment. Yet the patient became
nonresponsive to fluconazole, which was substituted with
itraconazole (100mg bid every 2 days).
One year ago, she started an alternative medical treat-
ment that included simultaneous intake of cranberry tablets
(containing 700mg cranberry extract conc Tit 1%, intake
of proanthocyanidin 7mg, grapefruit seeds dry extract 4/1
100mg, Orthosiphon titrated dry extract 0.2% 100mg, intake
of sinensetin 0.2mg, and goldenrod titrated dry extract 10/1
100mg), probiotics (containing vitamin B1 0.42mg, vitamin
B2 0.48mg, vitamin B6 0.6mg, niacin 5.4mg, vitamin B5
1.8mg, vitamin B12 0.3𝜇g, and total milk enzymes: L. rham-
nosus, L. acidophilus, Streptococcus thermophilus, Bifidobac-
terium bifidum, and L. bulgaricus, living cells not less than
2 billion), L-arginine (2 tablets/day, arginine hydrochloride
1000mg in one serving capsule), and 1 tablet of magnesium
at night (magnesium oxide 300mg in each serving capsule).
Following this regimen, the frequency and urgency to urinate
decreased and UTI recurred after 2 month. Afterwards, she
started taking garlic softgel tablets (serving size 2 softgels:
garlic oil 4.6mg, 500 : 1 concentrate equal to 2300mg fresh
garlic) and parsley seed oil tablets (110 𝜇g, 2000 : 1 concentrate
equal to 220mg fresh parsley). These have shown a decrease
in the UTI recurrence to 6-7 months and eventually no
recurrence was recorded for the last 12 months. Moreover,
the severity of recurrence has decreased and response to
antibiotics has become more pronounced. Later when she
discontinued garlic intake and became noncompliant to this
treatment, UTI reappeared after 2 months.
3. Case 2
A 28-year-old female presented with the history of rUTI
since the age of 23. The patient’s symptoms include burning
sensations in the lower area with stabbing-like pain, urgency,
and dysuria followed by hesitancy. The patient also reported
a high frequency of urination, reaching 10 times/hr. In
her first recurrent episode, urinalysis revealed pyuria (8–
10WBCs/hpf) and positive nitrites test and E. coli culture.
Then, ciprofloxacin was prescribed (500mg bid for 5 days)
and she experienced 2-3 recurrence episodes with positive E.
coli cultures. Later on, resistance to ciprofloxacin was devel-
oped with pelvic echogram and cystoscopy not showing any
abnormality, while urinalysis showed persistent bacteriuria
and cultures of E. coli resistant to fluoroquinolones.
Along with recurrent UTI over the years, interstitial
cystitis also started in addition to chronic daily symptoms
of overreactive bladder, urgency, frequency, and pubic pain.
Nitrofurantoin (2 tablets/day) was prescribed along with flu-
voxamine (1 tablet t.i.d.) to alleviate symptoms of overreactive
bladder. Her previous history included no sexual activity
for the last 4 years, persistent constipation, healthy diet and
lifestyle, inadequate water intake, and the use of intimate
perfumed washing gel fragranced, panty-liners and synthetic
polyester lingerie, and back to front wiping hygiene.
With time the patient entered a depression due to
the rUTI with persistent E. coli cultures and the chronic
interstitial cystitis that remained untreatable. An alternative
treatment regimen was prescribed and it included cranberry
tablets (1 tablet t.i.d.), probiotics (1 tablet before breakfast and
dinner), garlic and parsley (6 tablets at night), magnesium
tablets (2 tablets 300mg each at night), evening primrose
oil (2 tablets after lunch), and L-arginine (500mg, 1 tablet
t.i.d.). Several weeks following this regimen, the patient’s
symptoms including an overreactive bladder diminished,
and urgency, frequency, and pubic pain decreased by 80%.
Cultures remained negative and the patient experienced
only one interstitial cystitis episode, which was alleviated
with L-arginine (1000mg), magnesium tablets, and sustained
hydration.
4. Discussion
The failure of conventional antibiotic therapy to prevent and
treat rUTI due to antibiotic resistance represents a major
concern in clinical practice nowadays. Hence, alternative
therapy has emerged to help many young women relief
their symptoms, prevent the recurrence, and decrease the
frequency of bacterial resistance [10]. In this study, we report
an effective comprehensive, alternative therapeutic regimen
for treating and preventing rUTIs, which are nonresponsive
to most commonly used clinical protocols and guidelines.
For women suffering from rUTI, conventional man-
agement is based on low-dose antibiotic prophylaxis using
trimethoprim-sulfamethoxazole (40mg/200mgdaily), nitro-
furantoin (100mg/day), or cephalexin (250mg daily) [11].
However, the use of trimethoprim-sulfamethoxazole is lim-
ited to patients with resistance rates not exceeding 20% and
without allergy to sulfa drugs [5, 9]. However, these antibi-
otics have potentially fatal side effects, where nitrofurantoin
may lead to respiratory distress and liver injury [9]. Addi-
tionally, the FDA has recently issued a new warning on flu-
oroquinolone intake due to its association with a permanent
neuropathy and increased risk of retinal detachment [12].
The problem of antibiotic resistance is also on the rise since
womenwith frequent recurrent infections and symptoms can
self-initiate a 3-day regimen of antibiotics therapy without
consulting a physician. Due to the increasing resistance of
uropathogenic bacteria to different antibiotics, carbapenems
and ertapenem remain the last line of defense that requires
cautious use and are reserved only to cases of recurrent UTI
due to ESBL strains of uropathogenic E. coli [13].
Several factors have contributed to the relative success of
this treatment regimen. The significance of this regimen is
Case Reports in Medicine 3
attributed to the fact that the symptoms of UTI disappeared
for a longer duration of time compared to previous recurrent
UTIs in the described cases. As a result, this regimenmay aid
in decreasing the use of antibiotics amongUTI patients along
with the risk for developing resistance to antibiotics. The
persistence of bacteriuria in the first case and its absence in
the second case could be attributed to the serious compliance
to the given regimen of the second patient over the other.
Furthermore, apigenin, the main component of parsley,
was shown to possess diuretic effects in addition to anti-
inflammatory properties, which are essential in the treatment
of UTIs [14, 15]. Garlic in turn is well known for its antibacte-
rial, antifungal, and antiviral properties, which are attributed
to diallyl thiosulphate (allicin) and other sulfur containing
compounds [16, 17]. Garlic also exhibits antioxidant, anti-
inflammatory, and immune-modulatory effects that aid in the
treatment of interstitial cystitis [18]. Very few studies have
been conducted on the effect of garlic in the treatment of
UTIs, but one study has revealed that garlic had a significant
effect on attenuating the virulence of Pseudomonas aerugi-
nosa in vivo, in an experimental UTI model [19]. Therefore,
the combination of garlic oil and parsley in pills could have
a synergistic effect on bacterial growth and proliferation.
Moreover, cranberry contains significant amounts of D-
mannose, which is able to adhere to the bladder epithelium,
thus interfering with the adherence of E. coli and causing it to
simply wash away during urination [20]. The importance of
cranberry has been shown in a randomized clinical trial that
demonstrated a decrease in UTI recurrence over a period of
6 months [21]. Besides, a recent study examined the use of
cranberry pills as prophylaxis of rUTI in women and found
that it reduced the recurrence rate to 1.1 per year, and itwas the
most cost-effective method of all other therapies tested [22].
During sexual activity, the urinary tract may be colonized
by bacteria that move from the bowel or vagina [23]. Hence,
oral probiotics preparations are used to help repopulate the
normal flora in the GI tract. Probiotics are thought to aid
the GI tract or vagina to resist invasion and adhesion of
uropathogens, regulate intestinal flora, decrease constipation
at the right doses, enhance the immune system, and increase
the population of Lactobacillus that modulate local pH [24].
ADutch double-blind trial has shown that a preparation con-
taining Lactobacillus rhamnosus decreased antibiotic resis-
tance as compared to trimethoprim-sulfamethoxazole [25].
Other studies have shown that Lactobacillus preparations
restored and maintained the normal flora in women [26],
increased the number of lactobacilli [27], improved vaginal
health [28], and caused a relief from symptoms of UTI in
women [29]. Hence, restoring a balanced microbial flora is
essential in the presence of various UTI-promoting factors
such as synthetic lingerie, intimate perfumed washing gel,
and tampons. Besides, the aforementioned protocol has a
component with anti-inflammatory activity, which makes it
useful for both UTIs and cystitis.
The oxidation of L-arginine by nitric oxide synthase
results in the formation of nitric oxide (NO), which exhibits
antibacterial, smooth muscle relaxation, hormone releasing,
and immune modulating properties [30]. Furthermore, a
high concentration of NO can inhibit the growth of different
microorganisms, decrease oxidative stress, and regulate and
regenerate bladder uroepithelial cells, as well as alleviating
and treating interstitial cystitis [31].Thus, L-arginine can play
an important role as a prophylaxis after treatment of UTIs
to prevent the development of new infections as well as the
treatment of an overreactive bladder. Alternatively, magne-
sium produces a double effect since it can aid in reducing
constipation, hence decreasing the recurrence frequency, as
well as relaxing the smooth muscle of the bladder leading to
less frequent urination [10].
In light of the current common clinical outcomes ofUTIs,
the need for alternative therapeutic modalities to antibiotics
has become more crucial, especially for rUTIs. In addition,
the increased rate of hospitalization and its costs increases
the risk of acquiring ESBL-producing E. coli that are resistant
to several antibiotics [10].The current alternative approach is
a comprehensive regimen that can work effectively not only
in prophylaxis but also in rUTI, due to its anti-inflammatory
and bacteriostatic components. Hence, women having a first
episode of acuteUTI can follow this regimen to prevent future
recurrence. Overall, this comprehensive treatment regimen
can be initiated whenever symptoms reappear, with positive
bacterial cultures, and L-arginine will be used particularly to
relieve patients from overreactive bladder without conferring
risk of pyelonephritis. This regimen can also be used alone
or complementary to conventional treatment modality, and
if the symptoms did not resolve within 3 days, patients
can continue on a 7-day regimen along with antibiotics to
decrease their urinary tract bacterial load.
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